← Back to Screener
Rocket Pharmaceuticals, Inc. Common Stock (RCKT)
Price$2.75
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-27.52%
Price vs S&P 500 (4W)-24.23%
VGM Score31.14
Market Capitalization$299.74M
All Metrics
Book Value / Share (Quarterly)$2.18
P/TBV (Annual)1.51x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.65
Price vs S&P 500 (YTD)-29.81%
EPS (TTM)$-1.88
10-Day Avg Trading Volume2.41M
EPS Excl Extra (TTM)$-1.88
EPS (Annual)$-2.01
ROI (Annual)-74.75%
Cash / Share (Quarterly)$1.32
ROA (Last FY)-67.52%
EBITD / Share (TTM)$-1.84
ROE (5Y Avg)-53.74%
Cash Flow / Share (Annual)$-1.76
P/B Ratio1.26x
P/B Ratio (Quarterly)1.64x
Net Income / Employee (Annual)$-1,104,600
Net Interest Coverage (TTM)-27.98x
ROA (TTM)-59.62%
EV / EBITDA (TTM)29.99x
EPS Incl Extra (Annual)$-2.01
Current Ratio (Annual)6.38x
Quick Ratio (Quarterly)5.90x
3-Month Avg Trading Volume3.01M
52-Week Price Return-0.72%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.95
52-Week High$5.45
EPS Excl Extra (Annual)$-2.01
CapEx CAGR (5Y)-56.75%
Tangible BV CAGR (5Y)93.85%
26-Week Price Return-19.59%
Quick Ratio (Annual)6.25x
13-Week Price Return-40.73%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)6.12x
Enterprise Value$271.40M
Book Value / Share Growth (5Y)-20.88%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.74
3-Month Return Std Dev77.09%
Net Income / Employee (TTM)$-1,036,500
ROE (Last FY)-80.49%
Net Interest Coverage (Annual)-151.54x
EPS Basic Excl Extra (Annual)$-2.01
Total Debt / Equity (Quarterly)0.09x
EPS Incl Extra (TTM)$-1.88
ROI (TTM)-66.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.33
Price vs S&P 500 (52W)-25.09%
Year-to-Date Return-21.65%
5-Day Price Return-8.94%
EPS Normalized (Annual)$-2.01
ROA (5Y Avg)-46.83%
Month-to-Date Return-10.42%
Cash Flow / Share (TTM)$-3.08
EBITD / Share (Annual)$-1.99
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-50.99%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.88
P/TBV (Quarterly)1.83x
P/B Ratio (Annual)1.37x
Book Value / Share (Annual)$2.56
Price vs S&P 500 (13W)-48.99%
Beta0.50x
Revenue / Share (TTM)$0.00
ROE (TTM)-70.79%
52-Week Low$2.40
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.42est. -0.42
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.71
3.65
3.65
3.65
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RCKTRocket Pharmaceuticals, Inc. Common Stock | — | — | D | $2.75 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Rocket Pharmaceuticals is a late-stage biopharmaceutical company developing gene therapies for rare pediatric genetic diseases. Its pipeline includes five programs targeting Danon Disease, Fanconi Anemia, Leukocyte Adhesion Deficiency, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.